Common Contracts
2 similar Master Formulation Development Agreement contracts by Edge Therapeutics, Inc.
ContractMaster Formulation Development Agreement • May 5th, 2020 • Delaware
EX-10.1 2 ex10_1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. Execution Copy AMENDED AND RESTATED MASTER FORMULATION DEVELOPMENT AGREEMENT This Amended and Restated Master Formulation Development Agreement (the “Agreement”), dated June 30, 2017 (the “Amendment and Restatement Effective Date”), is made by and between Oakwood Laboratories, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146 (“Oakwood”), and Edge Therapeutics, Inc., a New Jersey corporation having an address of 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 (“Edge”). Edge and Oakwood are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Recitals Whereas, Edge is engaged in the development of polymer-based sustained-release injectable drug products; Whereas, Oakwood is engaged in the lice
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS.Master Formulation Development Agreement • August 1st, 2017 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Master Formulation Development Agreement (the “Agreement”), dated June 30, 2017 (the “Amendment and Restatement Effective Date”), is made by and between Oakwood Laboratories, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146 (“Oakwood”), and Edge Therapeutics, Inc., a New Jersey corporation having an address of 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 (“Edge”). Edge and Oakwood are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
